MedTrace Logo

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00072930 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-01-15

No results posted yet for this study

Summary

The primary objectives of this study are:

1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC); and
2. To summarize the safety of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in this patient population.

Conditions

Interventions

BIOLOGICAL

MEDI-522

IV at a concentration of 50 mg/mL and 10mL vials

BIOLOGICAL

Docetaxel + Prednisone* + Zoledronic Acid

IV 75 mg/m2 IV 3-4 mg 5 mg

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Luz Hammershaimb, MD · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2007-04-30
Completion
2007-06-30

Countries

  • United States
  • Belgium
  • Canada
  • Hungary
  • Israel
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00072930 on ClinicalTrials.gov